Literature DB >> 8450215

Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.

N Rachamim1, C L Jaffe.   

Abstract

A protein purified from Leishmania donovani promastigotes, dp72, was shown to partially protect BALB/c mice against a challenge by this parasite. Immunized mice infected i.v. with 10(7) L. donovani promastigotes showed a 0, 60, and 78% reduction in liver parasite burden compared with the control mice at each time point examined after challenge, 1, 20, and 108 days, respectively. Western blotting demonstrated that the sera from the immune mice, which reacted specifically with dp72 in lysates of L. donovani, cross-reacted with one major band in total homogenates of Leishmania major and Leptomonas collosoma. Lymphocyte proliferation to crude and pure parasite Ag was also examined in mice immunized with dp72. Strong proliferation was found at low concentrations of crude L. donovani Ag (0.5 micrograms/ml) and with pure dp72. Proliferation at higher concentrations to crude L. major and L. collosoma Ag was observed. Little or no reaction (stimulation index < 1.0) was seen with other pure leishmanial Ag, including gp70-2, the promastigote surface protease, and lipophosphoglycan. Depletion in vitro of the CD4+ T cell subset from immune spleen cells abolished proliferation to dp72, whereas depletion of CD8+ T cells enhanced proliferation to the pure Ag. Experiments in vivo showed that immunized mice treated with antibodies to either CD4+, CD8+, both T cell subsets, or to IFN-gamma had larger LPB (178, 173, 176, and 130%, respectively) after challenge with L. donovani than nonimmunized controls. Mice immunized with dp72 but treated with either PBS or mouse Ig showed reduced LPB, 81 and 61%, respectively, compared with the nonimmunized animals. BALB/c mice immunized with dp72 were also protected against L. major which causes cutaneous leishmaniasis. Immunized mice infected with either 10(4) or 10(6) promastigotes did not develop lesions. Limiting dilution assays confirmed the protection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450215

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis.

Authors:  S Mukhopadhyay; S Bhattacharyya; R Majhi; T De; K Naskar; S Majumdar; S Roy
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

Authors:  P C Melby; G B Ogden; H A Flores; W Zhao; C Geldmacher; N M Biediger; S K Ahuja; J Uranga; M Melendez
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Previous exposure to a low infectious dose of Leishmania major exacerbates infection with Leishmania infantum in the susceptible BALB/c mouse.

Authors:  Catherine S Nation; Blaise Dondji; Gabrielle A Stryker
Journal:  Parasitol Res       Date:  2012-04-04       Impact factor: 2.289

5.  Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Authors:  Blaise Dondji; Eva Pérez-Jimenez; Karen Goldsmith-Pestana; Mariano Esteban; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.

Authors:  Ingrid Aguilar-Be; Renata da Silva Zardo; Edilma Paraguai de Souza; Gulnara Patrícia Borja-Cabrera; Miguel Rosado-Vallado; Mirza Mut-Martin; Maria del Rosario García-Miss; Clarisa Beatriz Palatnik de Sousa; Eric Dumonteil
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

9.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

10.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.